Table 2.
Outcome of the neurological examinations, the symptom severity score and assessment of quality of life with doxycycline and placebo treatment
| |
Doxycycline 3 weeks |
Placebo 3 weeks |
||||
|---|---|---|---|---|---|---|
| Patient no. | Neurological examination | SSS symptom 1/2 | SF-36 PCS/MCS | Neurological examination | SSS symptom 1/2 | SF-36 PCS/MCS |
| 1 |
0 |
N.A |
+/+ |
0 |
N.A |
−/− |
| 2 |
+ |
+/+ |
N.A |
0 |
-/0 |
+/+ |
| 3 |
0 |
N.A |
−/+ |
0 |
N.A |
N.A |
| 4 |
0 |
0/0 |
+/− |
0 |
0/0 |
N.A |
| 5 |
0 |
+/− |
+/− |
0 |
0/+ |
0/+ |
| 6 |
0 |
0/+ |
−/− |
0 |
0/0 |
N.A |
| 7 |
0 |
0/+ |
N.A |
0 |
0/- |
−/+ |
| 8 |
0 |
0/+ |
+/− |
0 |
+/+ |
−/+ |
| 9 |
0 |
+/N.A |
+/+ |
0 |
-/N.A |
−/+ |
| 10 |
0 |
+/+ |
+/+ |
+ |
0/+ |
−/+ |
| 11 |
0 |
0/0 |
−/+ |
+ |
0/0 |
−/+ |
| 12 |
0 |
0/0 |
−/− |
0 |
0/+ |
+/− |
| 13 |
0 |
-/0 |
−/+ |
+ |
-/0 |
+/− |
| 14 |
0 |
0/N.A |
−/+ |
0 |
0/N.A |
N.A |
| 15 | 0 | 0/0 | +/− | 0 | 0/0 | +/+ |
A difference between the results of the examinations and assessments after and before treatment was used for comparison of the outcome of treatment, and was defined as: +, improvement; 0, unchanged or –, worse. For the SSS, the two symptoms (symptom 1 and 2) with the highest severity scores were chosen for comparison. No significant differences were found in any of the outcome measures either within or between the doxycycline and placebo treatment groups. no, number; SSS, symptom severity score; SF-36, Short Form-36; PCS, physical component summary; MCS, mental component summary; N.A, not analyzed.